№ files_lp_4_process_3_087878
Phase 2 clinical trial data including pharmacokinetic measurements, health-related quality of life assessments, and demographic distribution for patients with advanced or metastatic claudin 18.2–positive gastric or gastroesophageal junction adenocarcinoma across multiple countries and treatment cohorts.
Year: 2023
Study Type: Clinical trial, Phase 2
Document Type: Supplementary data
Authors: Samuel J. Klempner et al.
Intervention: Zolbetuximab monotherapy, Zolbetuximab + mFOLFOX6, Zolbetuximab + Pembrolizumab
Population: Patients with advanced or metastatic claudin 18.2–positive gastric or gastroesophageal junction adenocarcinoma
Sample Size: 54
Countries: France, Italy, Japan, Korea, Taiwan, United States
Cohorts: 1A, 2, 3A
Age Range: 32–79 years
Median Age: 60–65 years
Sex Distribution: Male 33, Female 21
Ethnicity: Asian 43%, White 43%, Black 2%, Hispanic/Latino 6%
PK Sampling: Zolbetuximab, mFOLFOX, Pembrolizumab
HRQOL Assessment: Multiple cycles per cohort
Follow-up: 30-day safety, 90-day follow-up
Geographic Focus: Eastern Asia, Central/Eastern Europe, United States, France
End Points: Pharmacokinetics, health-related quality of life, patient demographics
Data Sources: Clinical study data, GLOBOCAN 2020, literature references
Supplementary Materials: Methods, Tables, Figures
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.